Liqi Feng Selected Research

mazdutide

1/2022	A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.
9/2021	IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Liqi Feng Research Topics

Disease

2	Obesity 01/2022 - 09/2021
2	Type 2 Diabetes Mellitus (MODY) 01/2022 - 09/2021
2	Renal Insufficiency (Renal Failure) 01/2018 - 01/2018
2	Stroke (Strokes) 01/2018 - 01/2018
1	Nausea 01/2022
1	Overweight 09/2021
1	Heart Diseases (Heart Disease) 09/2021
1	Body Weight (Weight, Body) 09/2021
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2021
1	Chronic Renal Insufficiency 01/2021
1	Lung Neoplasms (Lung Cancer) 12/2020
1	Endocarditis 10/2020
1	Infections 01/2020
1	Wound Infection (Wound Infections) 01/2018
1	Mediastinitis 01/2018

Drug/Important Bio-Agent (IBA)

2	mazdutideIBA 01/2022 - 09/2021
2	Glucagon Receptors (Glucagon Receptor)IBA 01/2022 - 09/2021
2	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2022 - 09/2021
1	dulaglutideIBA 01/2022
1	Pharmaceutical PreparationsIBA 10/2020

Therapy/Procedure

3	Length of Stay 01/2020 - 01/2018
1	Operative Time 01/2021
1	Thoracotomy 01/2021
1	Segmental Mastectomy (Lumpectomy) 12/2020
1	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2018